Related Experiment Video

Updated: Apr 15, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

Mark C Markowski, Kenneth J Pienta1

  • 1Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Asian Journal of Andrology
|April 14, 2015
PubMed

Insights

Metastatic prostate cancer remains a significant threat, with numerous new treatments available. Determining the optimal sequence for these therapies, especially considering patient symptoms, is crucial for effective care.

Area of Science:

  • Oncology
  • Medical Therapeutics

Background:

  • Metastatic prostate cancer causes approximately 30,000 male deaths annually.
  • Five new FDA-approved agents target metastatic castration-resistant prostate cancer (mCRPC) since 2010.

Purpose of the Study:

  • To address the challenge of selecting the most effective treatment sequence for mCRPC.
  • To propose the development of treatment algorithms based on symptom presentation.

Main Methods:

  • Review of current therapeutic agents and treatment guidelines for mCRPC.
  • Analysis of symptom status (asymptomatic, moderate, symptomatic) as a decision-making parameter.

Main Results:

  • The optimal sequence for mCRPC therapies is currently unknown.
  • Symptom presence (bony pain, visceral crisis) is a critical factor in treatment decisions.

Conclusions:

  • Treatment sequencing for mCRPC requires further investigation.
  • Development of distinct treatment algorithms for asymptomatic, moderately symptomatic, and symptomatic patients is needed.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K
Retzius-Sparing Robot-Assisted Radical Prostatectomy12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

10.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.5K